Research published in the Lancet finds no benefit for hydroxychloroquine against Covid-19

Allie Nawrat 22 May 2020 (Last Updated May 22nd, 2020 15:30)

Research published today in The Lancet did not find any benefit of the use of hydroxychloroquine or chloroquine on in-hospital outcomes of Covid-19 patients.

In addition, the Harvard Medical School-led research found hydroxychloroquine or chloroquine both alone or in combination with a macrolide antibiotic was associated with "an increased risk of in-hospital death with Covid-19".

The research was carried out on almost 100,000 patients in over 670 hospitals across six continents and in real-world hospital settings.

The researchers conclude: "These findings suggest that these drug regimens should not be used outside of clinical trials and urgent confirmation from randomised clinical trials is needed."

There are multiple clinical trials of hydroxychloroquine and chloroquine ongoing at the moment. The most recently launched is University of Oxford-led CopCov study looking into the safety and efficacy of these drugs to prevent Covid-19.